JP2012532845A - 1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法 - Google Patents
1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法 Download PDFInfo
- Publication number
- JP2012532845A JP2012532845A JP2012518995A JP2012518995A JP2012532845A JP 2012532845 A JP2012532845 A JP 2012532845A JP 2012518995 A JP2012518995 A JP 2012518995A JP 2012518995 A JP2012518995 A JP 2012518995A JP 2012532845 A JP2012532845 A JP 2012532845A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- temperature
- process according
- episode
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002425 crystallisation Methods 0.000 title abstract description 16
- XTNGUQKDFGDXSJ-ZXGKGEBGSA-N Canagliflozin Chemical compound CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 XTNGUQKDFGDXSJ-ZXGKGEBGSA-N 0.000 title description 3
- 239000013078 crystal Substances 0.000 claims abstract description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 15
- -1 β-D-glucopyranosyl Chemical group 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 59
- 238000001816 cooling Methods 0.000 claims description 26
- 230000010355 oscillation Effects 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 21
- 238000001238 wet grinding Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000010951 particle size reduction Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010008 shearing Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000005549 size reduction Methods 0.000 claims description 5
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000010899 nucleation Methods 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 238000009826 distribution Methods 0.000 abstract description 27
- 239000002245 particle Substances 0.000 abstract description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 239000011362 coarse particle Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010904 focused beam reflectance measurement Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010947 wet-dispersion method Methods 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Description
oscillation episode)及び少なくとも1つの機械的粒度縮小エピソード(particle size reduction episode)を含むと、狭い粒度分布を有する結晶性1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼン半水和物(すなわち化合物(I))を得ることができることが見出された。そのようにして得られる結晶性化合物(I)は狭い粒度分布ならびに向上した流動性、嵩密度及びタップ密度性を有することが見出された。
●加熱前の出発温度
●加熱時間、加熱の速度及び温度/時間分布
●最高温度及びその持続時間(温度保持段階)
●冷却時間、冷却の速度及び温度/時間分布
●冷却後の最終的な温度。
solution)ことができる。振幅は、所望の溶解度の差に依存して5℃〜20℃の範囲であることができる。振幅は、各温度振動エピソードに関して同じか又は異なることができる。
a)化合物(I)が全部溶解し得る許す濃度及び温度条件下で、溶媒系中の化合物(I)の溶液を調製し;
b)該溶液を、溶液が準安定区域内にあるような温度に冷却し;
c)化合物(I)の溶液に化合物(I)の結晶を播種し;
d)化合物(I)の溶液を冷却して化合物(I)の結晶の懸濁液を得;
e)かくして形成される結晶懸濁液を、せん断機を用いる機械的粒度縮小に供し;
f)化合物(I)の結晶懸濁液を加熱して微粒子を溶解し;
g)段階d)、e)及びf)を1〜6回繰り返し;
h)化合物(I)の結晶懸濁液を室温もしくはそれより低温に冷却し;
i)かくして生成する化合物(I)の結晶を濾別する
連続段階を含んでなる結晶性化合物(I)の製造方法に関する。
●段階b):温度は52℃〜56℃の範囲、特に約54℃である
●段階c):約0.5%の量で化合物(I)の極微結晶を播種
●段階d):冷却は36℃〜40℃の温度、特に約38℃への立方温度分布に従う
●段階e):高せん断機を用いる湿式磨砕
●段階f):結晶性化合物(I)の懸濁液を52℃〜56℃の温度、特に約55℃に加熱する
●段階h):化合物(I)の結晶懸濁液を室温又はそれより低温、特に0℃に冷却する。
化合物(I)(1.59g)を播種し、混合物を2時間撹拌した。反応混合物を、下記の立方温度低下に従って冷ました:
●20分かけて52.4℃に
●20分かけて49.0℃に
●20分かけて44.4℃に
●20分かけて38℃に。
●25分かけて54.0℃に
●25分かけて52.4℃に
●25分かけて47.1℃に
●25分かけて38℃に。
●25分かけて54.0℃に
●25分かけて52.4℃に
●30分かけて41.4℃に
●105分かけて0℃に。
図1:4つの温度振動エピソード及び4つの機械的粒度縮小エピソードのグラフ図。
図2:温度振動及び湿式磨砕のグラフ図。
図3:古典的な冷却又は非−溶剤結晶化により得られる化合物(I)の粒度分布。
図4:実施例1に記載された温度振動及び高せん断機を用いる湿式磨砕を用いて得られる化合物(I)の粒度分布。
Claims (15)
- 溶媒系中の1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼン半水和物の結晶懸濁液を、少なくとも1つの温度振動エピソード(temperature oscillation episode)及び少なくとも1つの機械的粒度縮小エピソード(particle size reduction episode)に供する1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼン半水和物結晶の製造方法。
- 温度振動エピソードが加熱段階及び対応する冷却段階を含む請求項1に従う方法。
- 加熱段階が冷却段階に先行する請求項2に従う方法。
- 機械的粒度縮小を湿式磨砕により行う請求項3に従う方法。
- 温度振動エピソードが機械的粒度縮小エピソードに先行する請求項4に従う方法。
- 温度振動エピソード及び機械的粒度縮小エピソードを互いに独立して繰り返す請求項4に従う方法。
- 溶媒系が、1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼン半水和物が温度振動エピソードの最低温度と最高温度の間で溶解度における大きな差を有する有機溶媒又は有機溶媒の混合物である請求項1〜6のいずれか1つに従う方法。
- 溶媒系が酢酸エチル、酢酸1−メチルエチル又はそれらの混合物から選ばれ、該溶媒系が場合により最高で20%の水を含んでなることができる請求項7に従う方法。
- a)化合物(I)が全部溶解し得る濃度及び温度条件下で、溶媒系中の化合物(I)の溶液を調製し;
b)該溶液を、溶液が準安定区域内にあるような温度に冷却し;
c)化合物(I)の溶液に化合物(I)の結晶を播種し;
d)化合物(I)の溶液を冷却して化合物(I)の結晶の懸濁液を得;
e)かくして形成される結晶懸濁液を、せん断機を用いる機械的粒度縮小に供し;
f)化合物(I)の結晶懸濁液を加熱して微粒子を溶解し;
g)段階d)、e)及びf)を1〜5回繰り返し;
h)化合物(I)の結晶懸濁液を室温もしくはそれより低温に冷却し;
i)かくして生成する化合物(I)の結晶を濾別する
連続段階を含んでなる請求項1の方法。 - 段階a)における溶媒系が酢酸1−メチルエチル及び水の混合物である請求項9に従う方法。
- 段階b)における温度が54℃である請求項10に従う方法。
- 段階d)における化合物(I)の溶液の冷却が立方温度低下(cubic temperature decrease)に従う請求項11に従う方法。
- 段階f)において化合物(I)の結晶懸濁液を55℃に加熱する請求項12に従う方法
。 - 段階d)、e)及びf)を1回繰り返す請求項13に従う方法。
- 段階h)において化合物(I)の結晶懸濁液を0℃に冷却する請求項14に従う方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09165125 | 2009-07-10 | ||
EP09165125.7 | 2009-07-10 | ||
PCT/EP2010/059817 WO2011003976A1 (en) | 2009-07-10 | 2010-07-08 | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012532845A true JP2012532845A (ja) | 2012-12-20 |
JP5658751B2 JP5658751B2 (ja) | 2015-01-28 |
Family
ID=41137363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012518995A Active JP5658751B2 (ja) | 2009-07-10 | 2010-07-08 | 1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8772512B2 (ja) |
EP (1) | EP2451797B1 (ja) |
JP (1) | JP5658751B2 (ja) |
KR (1) | KR101532412B1 (ja) |
CN (1) | CN102482250B (ja) |
AU (1) | AU2010270202B2 (ja) |
CA (1) | CA2767258C (ja) |
CY (1) | CY1114404T1 (ja) |
DK (1) | DK2451797T3 (ja) |
EA (1) | EA022186B1 (ja) |
ES (1) | ES2416459T3 (ja) |
HR (1) | HRP20130561T1 (ja) |
PL (1) | PL2451797T3 (ja) |
PT (1) | PT2451797E (ja) |
SI (1) | SI2451797T1 (ja) |
WO (1) | WO2011003976A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018500368A (ja) * | 2014-12-25 | 2018-01-11 | 重慶医薬工業研究院有限責任公司 | カナグリフロジンの結晶形i及びその製造方法 |
JP2019504022A (ja) * | 2015-12-21 | 2019-02-14 | ヤンセン ファーマシューティカ エヌ.ベー. | カナグリフロジン半水和物結晶を得るための結晶化手順 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2911261A1 (en) | 2013-05-08 | 2014-11-13 | Lek Pharmaceuticals D.D. | Novel crystalline hydrates of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
CN103641822B (zh) * | 2013-10-21 | 2016-06-08 | 江苏奥赛康药业股份有限公司 | 一种卡格列净化合物及其药物组合物 |
EP2933255A1 (en) | 2014-04-17 | 2015-10-21 | LEK Pharmaceuticals d.d. | Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
CN104974146B (zh) * | 2014-09-15 | 2018-02-02 | 苏州晶云药物科技有限公司 | 坎格列净的晶型e、晶型f及其制备方法 |
ES2817526T3 (es) * | 2015-05-22 | 2021-04-07 | Janssen Pharmaceutica Nv | Forma cristalina anhidra de (1S)-1,5-anhidro-1-[3-[[5-(4-fluorofenil)-2-tienil]metil]-4-metilfenil]-D-glucitol |
CN108017626A (zh) * | 2016-11-04 | 2018-05-11 | 上海奥博生物医药技术有限公司 | 一种坎格列净半水合物新晶型 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518495A (ja) * | 1998-06-24 | 2002-06-25 | サノフィ−サンテラボ | イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物 |
JP2006515016A (ja) * | 2003-01-20 | 2006-05-18 | ノバルティス アクチエンゲゼルシャフト | 薬剤結晶形を修飾するための方法 |
WO2008069327A1 (en) * | 2006-12-04 | 2008-06-12 | Mitsubishi Tanabe Pharma Corporation | CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
US4160861A (en) | 1977-10-03 | 1979-07-10 | Merck & Co., Inc. | Method for the separation of antibiotic macrolides |
US4584369A (en) | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
CA1327013C (en) | 1988-06-23 | 1994-02-15 | Peter Rex Brawn | Cosmetic composition |
EP0355750B1 (en) | 1988-08-19 | 1995-01-25 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
DE59105613D1 (de) | 1990-08-24 | 1995-07-06 | Spirig Ag | Verfahren zur Herstellung von Pellets. |
EP0517969A1 (en) | 1991-06-10 | 1992-12-16 | AUSIMONT S.p.A. | Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide |
US5149838A (en) | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
US5610294A (en) | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
US5334225A (en) | 1992-07-15 | 1994-08-02 | Kao Corporation | Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler |
US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
CA2102591C (en) | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
US6297363B1 (en) | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
JP3187611B2 (ja) | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
JP3059088B2 (ja) | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
IL121525A0 (en) | 1996-08-26 | 1998-02-08 | Tanabe Seiyaku Co | Process for preparing optically active benzothiazepine compound and intermediate therefor |
DK0850948T3 (da) | 1996-12-26 | 2002-07-29 | Tanabe Seiyaku Co | Propiophenonderivater og fremgangsmåde til fremstilling deraf |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
JP3450810B2 (ja) | 2000-01-31 | 2003-09-29 | キヤノン株式会社 | 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびセルロースの再資源化方法 |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
BR0109323A (pt) | 2000-03-17 | 2002-12-24 | Kissei Pharmaceutical | Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
EP1172362A1 (de) | 2000-07-11 | 2002-01-16 | Basf Aktiengesellschaft | Azadioxacycloalkene und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen |
KR100426030B1 (ko) | 2000-07-22 | 2004-04-03 | (주) 한켐 | 락톤계 당화합물에서의 키랄성 전환방법 |
EP1338603B1 (en) | 2000-11-02 | 2010-01-20 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
JP2002167430A (ja) | 2000-12-01 | 2002-06-11 | Canon Inc | 脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびデンプンの資源化方法 |
US6476352B2 (en) | 2000-12-18 | 2002-11-05 | General Electric Company | Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor |
ES2326158T3 (es) | 2000-12-28 | 2009-10-02 | Kissei Pharmaceutical Co., Ltd. | Derivados de glucopiranosiloxipirazol y su utilizacion como medicamentos. |
DE60230591D1 (de) | 2001-02-26 | 2009-02-12 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
WO2002068440A1 (fr) | 2001-02-27 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
CA2444481A1 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
CA2672001A1 (en) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
JP4399254B2 (ja) | 2001-06-20 | 2010-01-13 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
US20030191121A1 (en) | 2001-08-09 | 2003-10-09 | Miller Ross A. | Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
AU2002337302A1 (en) | 2001-10-24 | 2003-05-06 | Michael Burton | Chromogenic enzyme substrates and method for detecting beta-d-ribofuranosidase activity |
JP2003238417A (ja) | 2002-02-18 | 2003-08-27 | Nippon Shoyaku Kenkyusho:Kk | フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品 |
US6617313B1 (en) | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
US6562791B1 (en) | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
JP2003313168A (ja) | 2002-04-18 | 2003-11-06 | Kirin Brewery Co Ltd | Bcl−2阻害活性を有する化合物およびその化合物のスクリーニング方法 |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
BR0310006A (pt) | 2002-08-09 | 2005-02-15 | Taisho Pharmaceutical Co Ltd | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos |
WO2004019958A1 (ja) | 2002-08-27 | 2004-03-11 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
AU2003279809A1 (en) | 2002-10-07 | 2004-05-04 | Encore Pharmaceuticals, Inc. | R-nsaid esters and their use |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
BR0317929A (pt) | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
EP1597266A4 (en) | 2003-02-27 | 2008-02-20 | Bristol Myers Squibb Co | NON-CRYOGENIC PROCESS FOR THE PRODUCTION OF GLYCOSIDES |
US7202350B2 (en) | 2003-03-14 | 2007-04-10 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
EP1637539B1 (en) | 2003-06-20 | 2012-01-18 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
KR20060058092A (ko) | 2003-07-23 | 2006-05-29 | 신타 파마슈티칼스 코프. | 염증 및 면역에 이용되는 화합물 |
CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
AR045173A1 (es) | 2003-08-01 | 2005-10-19 | Tanabe Seiyaku Co | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio |
AR048377A1 (es) | 2003-08-01 | 2006-04-26 | Janssen Pharmaceutica Nv | Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos |
CA2549025A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
EA009768B1 (ru) | 2003-08-01 | 2008-04-28 | Янссен Фармацевтика Нв | Замещенные конденсированные гетероциклические с-гликозиды |
WO2005058845A2 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
EA011158B1 (ru) | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006010557A1 (de) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
US20090124702A1 (en) | 2005-01-25 | 2009-05-14 | Pechetti Siva Satya Krishna Babu | Pharmaceutical Compositions of Metformin |
AR053329A1 (es) | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
ATE445608T1 (de) | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2) |
WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
JP5128474B2 (ja) | 2005-07-27 | 2013-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル−置換((ヘテロ)シクロアルキルエチニル−ベンジル)−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法 |
WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
CA2640090A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
US7858587B2 (en) | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
EP2079753A1 (en) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP5337040B2 (ja) | 2006-11-09 | 2013-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt−2インヒビターとの組み合わせ治療及びそれらの医薬組成物 |
US7666845B2 (en) | 2006-12-04 | 2010-02-23 | Janssen Pharmaceutica N.V. | Compounds having inhibitory activity against sodium-dependent glucose transporter |
EP1956023A1 (en) | 2007-02-06 | 2008-08-13 | Lonza Ag | Method for lithium exchange reactions |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
PL2187742T3 (pl) | 2007-08-23 | 2018-06-29 | Theracos Sub, Llc | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy |
HUE035130T2 (en) | 2007-09-10 | 2018-05-02 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as SGLT inhibitors |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
DK2488515T3 (en) | 2009-10-14 | 2017-02-27 | Janssen Pharmaceutica Nv | PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2 |
MX339570B (es) | 2010-05-11 | 2016-05-31 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio. |
-
2010
- 2010-07-08 JP JP2012518995A patent/JP5658751B2/ja active Active
- 2010-07-08 PL PL10729901T patent/PL2451797T3/pl unknown
- 2010-07-08 SI SI201030247T patent/SI2451797T1/sl unknown
- 2010-07-08 PT PT107299018T patent/PT2451797E/pt unknown
- 2010-07-08 US US13/382,658 patent/US8772512B2/en active Active
- 2010-07-08 EA EA201270153A patent/EA022186B1/ru not_active IP Right Cessation
- 2010-07-08 CN CN201080031854.6A patent/CN102482250B/zh active Active
- 2010-07-08 DK DK10729901.8T patent/DK2451797T3/da active
- 2010-07-08 WO PCT/EP2010/059817 patent/WO2011003976A1/en active Application Filing
- 2010-07-08 EP EP10729901A patent/EP2451797B1/en active Active
- 2010-07-08 AU AU2010270202A patent/AU2010270202B2/en active Active
- 2010-07-08 KR KR1020127002668A patent/KR101532412B1/ko active IP Right Grant
- 2010-07-08 CA CA2767258A patent/CA2767258C/en active Active
- 2010-07-08 ES ES10729901T patent/ES2416459T3/es active Active
-
2013
- 2013-06-18 HR HRP20130561AT patent/HRP20130561T1/hr unknown
- 2013-07-03 CY CY20131100551T patent/CY1114404T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518495A (ja) * | 1998-06-24 | 2002-06-25 | サノフィ−サンテラボ | イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物 |
JP2006515016A (ja) * | 2003-01-20 | 2006-05-18 | ノバルティス アクチエンゲゼルシャフト | 薬剤結晶形を修飾するための方法 |
WO2008069327A1 (en) * | 2006-12-04 | 2008-06-12 | Mitsubishi Tanabe Pharma Corporation | CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018500368A (ja) * | 2014-12-25 | 2018-01-11 | 重慶医薬工業研究院有限責任公司 | カナグリフロジンの結晶形i及びその製造方法 |
JP2019504022A (ja) * | 2015-12-21 | 2019-02-14 | ヤンセン ファーマシューティカ エヌ.ベー. | カナグリフロジン半水和物結晶を得るための結晶化手順 |
Also Published As
Publication number | Publication date |
---|---|
CN102482250A (zh) | 2012-05-30 |
SI2451797T1 (sl) | 2013-07-31 |
CA2767258A1 (en) | 2011-01-13 |
KR101532412B1 (ko) | 2015-06-29 |
PT2451797E (pt) | 2013-06-25 |
EA022186B1 (ru) | 2015-11-30 |
WO2011003976A1 (en) | 2011-01-13 |
AU2010270202B2 (en) | 2014-04-24 |
EP2451797A1 (en) | 2012-05-16 |
US20120108824A1 (en) | 2012-05-03 |
HRP20130561T1 (en) | 2013-07-31 |
CN102482250B (zh) | 2014-11-19 |
AU2010270202A1 (en) | 2012-01-19 |
CA2767258C (en) | 2016-09-13 |
EP2451797B1 (en) | 2013-04-03 |
US8772512B2 (en) | 2014-07-08 |
JP5658751B2 (ja) | 2015-01-28 |
KR20120046213A (ko) | 2012-05-09 |
ES2416459T3 (es) | 2013-08-01 |
CY1114404T1 (el) | 2016-08-31 |
PL2451797T3 (pl) | 2013-08-30 |
DK2451797T3 (da) | 2013-06-24 |
EA201270153A1 (ru) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5658751B2 (ja) | 1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法 | |
JP2010265295A (ja) | N−(トランス−4−イソプロピルシクロヘキシルカルボニル)−d−フェニルアラニンの結晶形 | |
JP4060658B2 (ja) | 小粒子調節晶出方法 | |
TW200810789A (en) | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use | |
KR20090113346A (ko) | 입도가 큰 타달라필 및 이의 제조 방법 | |
Belca et al. | The use of ultrasound in the crystallization process of an active pharmaceutical ingredient | |
JP2008520751A (ja) | 大粒子サイズを有するタダラフィル及びそれを調製する方法 | |
Fang et al. | Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization | |
JPS63294953A (ja) | 結晶質物質の製造方法 | |
WO2010071689A2 (en) | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative | |
CN106456548A (zh) | 包括含药物活性物质化合物的多孔材料 | |
JP6851379B2 (ja) | カナグリフロジン半水和物結晶を得るための結晶化手順 | |
EA020966B1 (ru) | Способ получения и очистки солей солифенацина | |
CN108191836A (zh) | 一种低静电厄贝沙坦原料药的制备方法 | |
KR101677539B1 (ko) | 파라세타몰 결정의 제조방법 | |
WO2013041944A1 (en) | Process for the preparation of micronized candesartan cilexetil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5658751 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |